Miacalcic

Calcitonin, the active ingredient in Miacalcic, is a peptide hormone presented as an injectable solution for intramuscular, intravenous or subcutaneous use. It treats hypercalcemia, postmenopausal osteoporosis, Paget's disease of bone, and bone pain associated with metastatic disease. It is indicated for patients with elevated serum calcium, reduced bone turnover, or skeletal complications due to malignancy.

GNH USA supplies Miacalcic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, with established cold‑chain logistics and regulatory support for cross‑border distribution.

Miacalcic is used in disorders of calcium metabolism and bone remodeling. - Hypercalcemia: lowers elevated serum calcium levels. - Postmenopausal osteoporosis: helps maintain bone density and reduce fracture risk. - Paget's disease of bone: normalizes abnormal bone turnover. - Bone pain associated with metastatic disease: provides analgesic benefit by reducing bone resorption.

Calcitonin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Flushing: transient warmth and redness. - Injection site pain: discomfort at the site of administration. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Hypocalcemia: excessive drop in serum calcium. - Severe allergic reaction: anaphylaxis or angioedema. - Osteonecrosis of the jaw: rare bone complication.

When prescribing Miacalcic, clinicians should consider several safety precautions. - Monitor calcium levels: check serum calcium before and during therapy. - Assess renal function: adjust use in patients with impaired kidney function. - Evaluate thyroid status: avoid use in patients with medullary thyroid carcinoma. - Caution in pregnancy: safety not established; use only if benefit outweighs risk. - Avoid in patients with known hypersensitivity to calcitonin or excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Calcitonin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Calcium supplements: may counteract the calcium‑lowering effect. - Bisphosphonates: concurrent use can increase risk of severe hypocalcemia.

Moderate Interactions (Monitor Closely): - Loop diuretics: may enhance calcium loss, requiring monitoring. - Corticosteroids: may reduce calcitonin’s bone‑protective effect. - Anticoagulants (e.g., warfarin): calcitonin may affect coagulation parameters.